659729-65-4

Usage

Chemical compound

5-hydroxy-2(1H)-quinoxalinone is a chemical compound.

Belongs to quinoxalinone group

It belongs to the quinoxalinone group of compounds.

Derivative of quinoxaline

It is a derivative of quinoxaline, a heterocyclic compound containing a benzene and a pyrazine ring.

Biological activities

It exhibits various biological activities, including antioxidant, anti-inflammatory, and antitumor properties.

Pharmaceutical agent

It has been investigated for its potential use as a pharmaceutical agent in the treatment of cancer and neurodegenerative diseases.

Signaling molecule

It has been studied for its ability to act as a signaling molecule in various cellular pathways.

Upstream product

• 59649-56-8 2,3-diaminophenol 
• 298-12-4 Glyoxilic acid 

Relevant academic research and scientific papers

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS

Pyrimidine ethers and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.